title: Autologous blood stem cell transplantation followed by recombinant alpha interferon as treatment for patients with high-risk chronic myelogenous leukemia. A report of 32 cases.
abstract: Autologous blood stem cell transplantation (ASCT) was performed in 32 patients with high risk chronic myelogenous leukemia (CML). Prior to ASCT, the patients were given Busulfan and high-dose Melphalan. Peripheral blood stem cells collected at diagnosis were used to rescue hematopoiesis. Recombinant Interferon was administered after ASCT. In 24 patients transplanted in transformation, 23 achieved a complete hematological response and nine are still alive 9 to 73 months after ASCT. Eight other patients were transplanted in chronic phase for either the presence of bad prognostic factors (Sokal's classification) or no response to IFN. Seven are alive without transformation 16 to 48 months after ASCT. Although few patients presented a cytogenetical response (10/28), the survival observed in this series of patients compares favorably with that of patients treated conventionally. Thus, the place of ASCT in CML could now be tested prospectively.
authors.affiliation: Bone Marrow Transplant Unit, CHR Bordeaux, France.
authors.forename: J
authors.initials: J
authors.lastname: Reiffers
authors.forename: M
authors.initials: M
authors.lastname: Montastruc
authors.forename: G
authors.initials: G
authors.lastname: Marit
authors.forename: P
authors.initials: P
authors.lastname: Cony-Makhoul
authors.forename: C
authors.initials: C
authors.lastname: Faberes
authors.forename: C
authors.initials: C
authors.lastname: Bilhou-Nabera
authors.forename: M J
authors.initials: MJ
authors.lastname: Gharbi
authors.forename: P
authors.initials: P
authors.lastname: Bernard
authors.forename: G
authors.initials: G
authors.lastname: Vezon
authors.forename: A
authors.initials: A
authors.lastname: Broustet
mesh_terms: D000328:Adult; D001752:Blast Crisis / Q000401:mortality / Q000628:therapy*; D016913:Blood Component Transfusion; D001804:Blood Transfusion, Autologous; D016465:Bone Marrow Purging; D002066:Busulfan; D003131:Combined Modality Therapy; D005602:France / Q000453:epidemiology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007370:Interferon Type I / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D015465:Leukemia, Myeloid, Accelerated Phase / Q000628:therapy*; D008558:Melphalan; D008875:Middle Aged; D011379:Prognosis; D011994:Recombinant Proteins; D012306:Risk; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D007155:Immunologic Factors; D007370:Interferon Type I; D011994:Recombinant Proteins; D002066:Busulfan; D008558:Melphalan